Primary Responsibilities:
This scientific role leads the ERA Group and is accountable for the strategy, quality, and timely delivery of environmental studies and risk assessments that characterize the interaction of Lilly therapeutics with the environment. The group leader serves as a people leader, scientific leader, strategic consultant, and technical expert for PiE-related issues across Lilly’s portfolio, manufacturing network, regulatory functions, and external engagement forums.
Lead the ERA Group by setting scientific direction, developing environmental scientists, and building environmental risk assessment capability across the portfolio.
Own portfolio ERA testing, prioritization, study governance, and submission-ready delivery for global regulatory registrations.
Direct execution of environmental studies that meet regulatory expectations through fit-for-purpose CRO partnerships that ensure GLP compliance, data quality, and reliable report delivery.
Advance Lilly’s diverse portfolio and ERA science by identifying and fostering innovative solutions and cross-functional collaboration.
Communicate ERA strategy, risks, decisions, and regulatory implications to Lilly leadership, project teams, and regulatory functions.
Advise manufacturing on pharmaceutical discharge limits and implementation strategies that protect people, ecosystems, and business continuity.
Lead PiE governance by assessing internal and external developments, framing business implications, and driving mitigation strategies through cross-functional partnership with GHSE, Governmental Affairs, R&D.
Represent Lilly externally to benchmark guidelines, influence regulatory expectations, shape industry positions, and guide external research engagement.